Injection combo shows promise for Hard-to-Treat skin cancer

NCT ID NCT07227350

Not yet recruiting Disease control Sponsor: Philogen S.p.A. Source: ClinicalTrials.gov ↗

First seen Nov 12, 2025 · Last updated May 23, 2026 · Updated 19 times

Summary

This study tests three different injected drugs (L19IL2, L19TNF, or a mix of both) in 180 people with advanced basal cell skin cancer who cannot have surgery or radiation. The drugs are injected directly into the tumor once a week for four weeks. The goal is to see which treatment shrinks the cancer best. Participants will be followed for up to three years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BASAL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.

Tampa, Florida, 33612, United States

Contact
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Winship Cancer Institute, Emory University

Atlanta, Georgia, 30322, United States

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED BASAL CELL CARCINOMA